Review clinical evidence and professional society guidelines demonstrating the benefits of A1C test for improving your patients with type 1 or type 2 diabetes outcomes.
OBM rapid A1c analyzes the deformability distributions of red blood cells in the capillary blood samples. In the distribution data, HbA1c level is inversely correlated with red blood cell deformability.
**This study was approved by the Institutional Review Board (IRB) of Orange Biomed Ltd., Co (2022-0594-007).
The clinical data of OBM rapid A1c exhibits high linearity (R2>0.998) with NGSP standard HbA1c%.
(*HbA1c% of each participant was measured using Afinion2 analyzer.)
**This study was approved by the Institutional Review Board (IRB) of Orange Biomed Ltd., Co (2022-0594-007).
Review peer-reviewed evidence and clinical studies demonstrating the new A1C test method and its performance.
Title: “Red Blood Cell Deformability” Based HbA1C Test
To be disclosed…
Professional societies continue to expand their recommendation of using A1C tests in patient care protocols for patients with type 1 or type 2 diabetes.
Stay informed about our launch and get exclusive updates straight to your inbox. Fill out the form below, and we’ll make sure you’re among the first to know when OBM rapid A1c test hits the market.
"*" indicates required fields
